Safety of smoking cessation drugs for mentally ill patients

Affiliations

¹ Centre for Addiction and Mental Health, Department of Pharmacology and Toxicology, Faculty of Medicine University of Toronto, 175 College Street, ON MST 1P7 Toronto, Canada. Electronic address: laurie.zawertailo@camh.ca.

Comment

Laurie Zawertailo. Lancet. 2016.

. 2016 Jun 18;387(10037):2481-2.

doi: 10.1016/S0140-6736(16)30294-X. Epub 2016 Apr 22.

¹ Centre for Addiction and Mental Health, Department of Pharmacology and Toxicology, Faculty of Medicine University of Toronto, 175 College Street, ON MST 1P7 Toronto, Canada. Electronic address: laurie.zawertailo@camh.ca.

No abstract available

Comment on

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. Anthenelli RM, et al. Lancet. 2016 Jun 18;387(10037):2507-20. doi: 10.1016/S0140-6736(16)30272-0. Epub 2016 Apr 22. Lancet. 2016. PMID: 27116918 Clinical Trial.